title: [Effect of chromium enriched fermentation product of barley and brewer's yeast and its combination with rosiglitazone on experimentally induced hyperglycaemia in mice].
abstract: BACKGROUND
  In the recent years, herbal preparations have been more used to treat diabetes. Dietetic supplement based on barley and beer yeast enriched with chromium (BBCr) is registered in Serbia as a supplement in the treatment of type 2 diabetes.
  
  
  OBJECTIVE
  To investigate the effect of the preparation based on barley and brewer's yeast with chromium (BBCr), rosiglitazone (R) and their combination (BBCr+R) on fasting glycaemia and glycaemia in mice after glucose, adrenalin and alloxan application.
  
  
  METHODS
  The animals were divided into three groups: glucose 500 mg/kg (I); adrenalin 0.2 mg/kg (II); and alloxan 100 mg/kg (III) and into subgroups according to the substance they received (BBCr: 750 mg/kg, R: 0.75 mg/kg and BBCr+R). Each animal was its own control in respect of glycaemia before and after the treatment with test substances, except for group III which contained a placebo subgroup.
  
  
  RESULTS
  BBCr caused a significant decrease of fasting glycaemia and significant reduction of glycaemia after glucose load compared to the values before treatment (7.4 +/- 0.6 mmol/l vs 9.2 +/- 0.6 mmol/l; p=0.01). R and BBCr+R significantly decreased glycaemia after adrenalin load (R: 8.6 +/- 1.8 mmol/l vs 15.4 +/- 3.2 mmol/l; p=0.004; BBCr+R: 9.6 +/- 2.4 mmol/l vs 15.0 +/- 4.4 mmol/l; p=0.04). After alloxan application the glycaemia was significantly lower in the subgroups treated with BBCr, R and BBCr+R compared to placebo subgroup (10.1 +/- 8.0 mmol/l vs 6.8 +/- 2.7 mmol/l vs 13.5 +/- 9.7 mmol/l vs 24.5 +/- 4.7 mmol/l; p=0.001).
  
  
  CONCLUSIONS
  Pretreatment with BBCr caused a significant reduction of fasting glycaemia and glycaemia after glucose load. Rosiglitazone and BBCr+R caused a significant reduction of glycaemia after adrenalin load. Pretreatment with BBCr, R and BBCr+R prevented the onset of experimental diabetes caused by alloxan, which was confirmed by histological analysis of pancreas tissue.
authors: Vlada
authors: V
authors: Cekić
authors: Velibor
authors: V
authors: Vasović
authors: Vida
authors: V
authors: Jakovljević
authors: Dušan
authors: D
authors: Lalošević
authors: Ivan
authors: I
authors: Čapo
authors: Momir
authors: M
authors: Mikov
authors: Ana
authors: A
authors: Sabo
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002857:Chromium / Q000008:administration & dosage*; D003921:Diabetes Mellitus, Experimental / Q000097:blood*; D019587:Dietary Supplements; D005285:Fermentation; D001467:Hordeum; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D051379:Mice; D000077154:Rosiglitazone; D012441:Saccharomyces cerevisiae; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D002857:Chromium